ETFs Omeros Corporation

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-14 EDT			5-day change	1st Jan Change
17.19 ^USD	-0.92%		+29.74%	+0.09%

08-13	Omeros Corporation Announces Appointment of Joseph Schocken as Director and Audit Committee Member, Effective August 12, 2026	CI
08-13	Omeros Swings to Q2 Adjusted Earnings; Shares up	MT

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.

Employees

175

Sector

Biotechnology & Medical Research

More about the company